Second-line treatment options are limited for patients with advanced non-small cell lung cancer (NSCLC). Standard therapy includes cytotoxic agents, docetaxel and pemetrexed, and the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), erlotinib and gefitinib. Immune checkpoint inhibitors are a new class of treatment that have shown durable overall radiological response rates and have been well tolerated. The objective of this systematic review was to investigate the efficacy of immune checkpoint inhibitors compared with other chemotherapies in patients with advanced NSCLC.
from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2kYcnQv
via IFTTT
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
Δημοφιλείς αναρτήσεις
-
Pulmonary complications post hematopoietic stem cell transplant in dyskeratosis congenita: analysis of oxidative stress in lung fibrobl...
-
Predictive Success Factors in Selective Upper Airway Stimulation. ORL J Otorhinolaryngol Relat Spec. 2017 Feb 24;79(1-2):121-128 Auth...
-
Abstract Background The introduction of aggressive chemo-radiotherapy regimens has improved overall survival in children with primitive ...
-
Background. Antitumor necrosis factor (anti-TNF) therapy is a highly effective but costly treatment for inflammatory bowel disease (IBD). Me...
-
6 Top Reference Sites to Write a Winning Research Paper . Tina 6 Top Reference Sites to Write a Winning Research Paper. There may be guideli...
-
by Mindaugas Paužuolis, Torsten Eich, Joachim Burman Background Natalizumab (NTZ) is a drug that has been widely used in the treatment of m...
-
Abstract Purpose To develop the first photoactive biomaterial coating capable of controlled drug dosing via inclusion of synthesised drug-...
-
Here is your sample essay on Advertising Advertising is an important element of our culture because it reflects and attempts to change our l...
-
We propose a new method applying matrix theory to analyse the instability conditions of unique homogeneous coexistent state of multispecies ...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου